Vanity Fair: Inside Psilocybin’s Big Week, from a Pioneering Depression Study to Election Day Wins

Summary: “Now with research percolating across the country, psychedelics are finding a broad base of support,” explains Vanity Fair, highlighting a growing shift in public acceptance of psychedelics, ranging from passing drug policy reform initiatives in the 2020 U.S. election to Dr. Bronner’s soap bottles citing psychedelic research on the shelves of prominent stores. David Bronner, CEO of Dr. Bronner’s and MAPS board member, comments on the ease of acceptance of Dr. Bronner’s Heal Soul campaign from mainstream retailers and offers his colorful perspective of MAPS Founder Rick Doblin, Ph.D.’s strategy to work with the FDA toward potential approval of MDMA-assisted psychotherapy for PTSD. “The way he’s working [with] the FDA, he’s kind of like Obi-Wan Kenobi on the Death Star, just working the system and moving MDMA through the FDA approval process,” explains Bronner.

Originally appearing here.